Schefer H, Lehmann B, Joss R
Praxis (Bern 1994). 1999 Apr 29;88(18):791-801.
In the last decade six new chemotherapeutic agents including the vinca alcaloid vinorelbine, the taxanes paclitaxel and docetaxel, the antimetabolite gemcitabine and the two topoisomerase I-inhibitors irinotecan and topotecan were shown to be active in several phase II- and randomized phase III-trials. This article reviews their mode of action, their efficacy, their side effects and their indications. Their state of registration and reimbursement by insurance companies in Switzerland are summarized. Finally, their costs and cost-effectiveness in a time of increasing financial restraint in health care budgets are analyzed.
在过去十年中，六种新型化疗药物，包括长春花生物碱长春瑞滨、紫杉烷类的紫杉醇和多西他赛、抗代谢药吉西他滨以及两种拓扑异构酶I抑制剂伊立替康和拓扑替康，在多项II期和随机III期试验中显示出活性。本文综述了它们的作用方式、疗效、副作用及适应证。总结了它们在瑞士的注册情况和保险公司的报销情况。最后，分析了在医疗保健预算面临日益严格的财务限制时期它们的成本和成本效益。
